1.Why Systematic Review rather than Narrative Review?.
Psychiatry Investigation 2015;12(3):417-419
No abstract available.
2.Evidence-Based Treatment for Depressive Disorder.
Psychiatry Investigation 2015;12(2):278-279
No abstract available.
Depressive Disorder*
3.Critics on "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study".
Psychiatry Investigation 2013;10(1):98-99
No abstract available.
Memantine
4.Patient Preference and Satisfaction in Decision-Making Process.
Journal of Korean Medical Science 2014;29(7):1030-1031
No abstract available.
*Anesthesia, General
;
Female
;
Humans
;
Male
;
*Patient Preference
;
*Patient Satisfaction
5.Influence of Media on Suicide: Proper Coverage of Media on Suicide Report.
Journal of Korean Medical Science 2014;29(11):1583-1585
No abstract available.
6.Filicide: Needing Psychiatrists' Attention.
Psychiatry Investigation 2014;11(2):214-215
No abstract available.
7.Serotonin Receptor 2C -759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.
Psychiatry Investigation 2014;11(3):342-343
No abstract available.
Humans
;
Serotonin*
8.The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder.
Psychiatry Investigation 2014;11(3):217-222
The immune hypothesis of major depressive disorder (MDD) fits well with the supposed interaction between genetic and environmental factors in disorders with a complicated etiopathogenesis. It has been suggested that infectious diseases are associated with MDD in that cytokines may play a critical role as a key modulator in the transition between infection and the development of MDD. It has been also suggested that antidepressants have immunomodulatory effects on some cytokines and cytokine receptors, although the exact mechanism has not yet been fully elucidated. Among cytokines, monocyte chemoattractant protein-1 (MCP-1) is especially well known and has attracted considerable interest owing to its immunomodulatory functions. MCP-1 is expressed in highly regionalized neuronal areas in the brain, leading to kind of modulation of neuronal activity and neuroendocrine functions commonly seen in patients with MDD. Additionally, it is involved in the control of other cytokines that have been consistently proposed as associated with the development of MDD. It also has a possible role in the neurodegenerative process of a number of central nervous system (CNS) diseases. Hence, this paper draws from the perspective of immunology to offer several suggestions about the role of MPC-1 in the development of MDD.
Allergy and Immunology
;
Antidepressive Agents
;
Brain
;
Central Nervous System
;
Chemokine CCL2*
;
Communicable Diseases
;
Cytokines
;
Depression
;
Depressive Disorder, Major*
;
Humans
;
Neurons
;
Receptors, Cytokine
9.The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder.
Psychiatry Investigation 2014;11(3):217-222
The immune hypothesis of major depressive disorder (MDD) fits well with the supposed interaction between genetic and environmental factors in disorders with a complicated etiopathogenesis. It has been suggested that infectious diseases are associated with MDD in that cytokines may play a critical role as a key modulator in the transition between infection and the development of MDD. It has been also suggested that antidepressants have immunomodulatory effects on some cytokines and cytokine receptors, although the exact mechanism has not yet been fully elucidated. Among cytokines, monocyte chemoattractant protein-1 (MCP-1) is especially well known and has attracted considerable interest owing to its immunomodulatory functions. MCP-1 is expressed in highly regionalized neuronal areas in the brain, leading to kind of modulation of neuronal activity and neuroendocrine functions commonly seen in patients with MDD. Additionally, it is involved in the control of other cytokines that have been consistently proposed as associated with the development of MDD. It also has a possible role in the neurodegenerative process of a number of central nervous system (CNS) diseases. Hence, this paper draws from the perspective of immunology to offer several suggestions about the role of MPC-1 in the development of MDD.
Allergy and Immunology
;
Antidepressive Agents
;
Brain
;
Central Nervous System
;
Chemokine CCL2*
;
Communicable Diseases
;
Cytokines
;
Depression
;
Depressive Disorder, Major*
;
Humans
;
Neurons
;
Receptors, Cytokine
10.New Treatment Option for Bipolar Depression:Focus on Novel Antiepileptic Drugs.
Korean Journal of Psychopharmacology 2001;12(2):106-114
Some novel antiepileptic drugs including lamotrigine and so on appear to have mood-stabilizing properties. Lamotrigine has the promising effets in terms of its efficacy in the treatment of bipolar depression. But its potential for developing fatal Stevens-Johnson syndrome is a weakpoint to apply in clinical field. Gabapentin appears to have partial effects in non-refractory bipolar depression according to uncontrolled and natu-ralistic data. Topiramate also has mild to moderate mood stabilizing efficacy in the treatment of bipolar depression and also, it has the advantage of losing weight, occasionally. In conclusion, with data to date, limited data show the possibility of novel antiepileptic drugs in the treatment of bipolar depression, but further research is required before clinicians can definitely grasp theses agents as inevitable option in the treatment of bipolar depression.
Anticonvulsants*
;
Bipolar Disorder
;
Hand Strength
;
Stevens-Johnson Syndrome